Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5906869 | 0.76 | ALDH1A1 (0.40) | SMN1; SMN2 | |
| SCHEMBL8154174 | 0.70 | ALDH1A1 (0.43) | SMN1; SMN2 | |
| SCHEMBL8154422 | 0.69 | — | — | |
| SCHEMBL5940600 | 0.69 | — | — | |
| SCHEMBL7253779 | 0.67 | — | — | |
| SCHEMBL8152565 | 0.67 | — | — | |
| SCHEMBL7254850 | 0.66 | — | — | |
| SCHEMBL7258099 | 0.66 | — | — | |
| SCHEMBL7254866 | 0.66 | — | — | |
| SCHEMBL7263484 | 0.66 | KDM4E (0.41) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060100224-A1 | Piperidine ouracil used as a medicament for treating bacterial infections | BAYER HEALTHCARE AG (DE) | 2006-05-11 | — | — | US | disclosed |
| EP-1499612-A1 | PIPERIDINE OURACIL USED AS A MEDICAMENT FOR TREATING BACTERIAL INFECTIONS | Bayer HealthCare AG (DE) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003072574-A1 | PIPERIDINE OURACIL USED AS A MEDICAMENT FOR TREATING BACTERIAL INFECTIONS | BAYER HEALTHCARE AG (DE) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100224-A1 | Piperidine ouracil used as a medicament for treating bacterial infections | BPGM, AMPD2, AMPD1 | SMN1; SMN2 3375/4885CREBBP 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.